Press Room


    Press Release - November 05, 2001

    Pheromone Sciences' PSC Fertility Monitor™ U.S. Trial Reaches Full Enrollment

    Pheromone Sciences Corp. (PHS: CDNX), today announced that it has achieved full enrollment of its USA based multi-center clinical trial for the PSC Fertility Monitor�¢ï¿½�¢.

    The clinical trial, designed to test the efficacy of the PSC Fertility Monitor, is being carried out at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at the Women's Institute for Fertility, Endocrinology and Menopause in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology, Thomas Jefferson University Hospital.

    "With the trial now fully enrolled, we intend to insure timely completion, data analysis, and reporting of results," said Christopher Neuman, President and CEO of Pheromone Sciences. "Results similar to those previously reported from the University of Toronto would provide the data required for marketing approval in the U.S."

    Frost and Sullivan in their October 2001 report titled, Innovative Medical Devices Straight from Science Fiction wrote In North America, medical devices and technologies are converging to revolutionize the consumer self-care market". Mr. Neuman goes on to state, "Our PSC Fertility Monitor is one such example of this marriage of biotechnology and diagnostics to provide women with a reliable predictive approach to natural, cycle based family planning designed in a small wrist-watch sized device".

    Subject to FDA approval, the PSC Fertility Monitor will be positioned in a marketplace of more than 5 million women across North America who are trying to conceive providing them with a personally customized, highly advanced diagnostic tool that can be used to provide up to 4 days advance notice of their pending ovulation. With this degree of advance notice, a women's ability to become pregnant increases significantly as most of the guesswork concerning timing of sexual relations to conceive can now be managed.

    It is anticipated that many of the women currently using urine strips and basal temperature methods to determine their ovulation date would find the PSC Fertility Monitor appealing based on its ability to provide increased advance notice (4 days), ease of use, and non invasive approach.

    "We are very pleased with the progress to date for this product. With the completion of the enrollment for the multi center trial coupled with the recent securing of the CE mark, the future marketability in North America and Europe for the PSC Fertility Monitor becomes more assured", stated Neuman.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Lorne Woods 1-(800) 937-3095


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News